Walid Abi-Saab, M.D., joined uniQure as Chief Medical Officer in June 2023. He is responsible for leading clinical research and development, regulatory affairs, medical affairs, and program management at uniQure.
Dr. Abi-Saab joins uniQure from the Belgium-based biopharmaceutical company Galapagos, where he served as Chief Medical Officer from 2017 through 2022. While at Galapagos, he expanded the company’s development organization and led the company through a critical and transformative phase, including the successful completion of the Phase 3 studies of filgotinib (Jyseleca®) in rheumatoid arthritis and ulcerative colitis. Prior to joining Galapagos, he served as Group Vice President, Global Clinical Development at Shire, where he was responsible for the clinical development plans of all programs in the therapeutic area and oversaw the development of more than 10 marketed products and other programs in rare diseases and specialty pharma. He also has previously held leadership positions at Novartis, Abbott Laboratories, and Pfizer, and served as a resident, research fellow, and assistant professor at Yale University School of Medicine, where he completed Psychiatry residency training and a Neuroscience Research Fellowship.
He obtained his bachelor’s degree in biology from the American University of Beirut, Lebanon and his M.D. at the Université Saint Joseph in Beirut.
What is Walid Abi-Saab's net worth?
The estimated net worth of Walid Abi-Saab is at least $6.50 million as of June 30th, 2026. Dr. Abi-Saab owns 148,235 shares of uniQure stock worth more than $6,503,069 as of August 5th. This net worth approximation does not reflect any other assets that Dr. Abi-Saab may own. Learn More about Walid Abi-Saab's net worth.
How do I contact Walid Abi-Saab?
The corporate mailing address for Dr. Abi-Saab and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at investors@uniqure. Learn More on Walid Abi-Saab's contact information.
Has Walid Abi-Saab been buying or selling shares of uniQure?
Walid Abi-Saab has not been actively trading shares of uniQure during the past quarter. Most recently, Walid Abi-Saab sold 30,000 shares of the business's stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.42, for a transaction totalling $1,392,600.00. Following the completion of the sale, the insider now directly owns 148,235 shares of the company's stock, valued at $6,881,068.70. Learn More on Walid Abi-Saab's trading history.
Who are uniQure's active insiders?
uniQure's insider roster includes Walid Abi-Saab (Insider), Madhavan Balachandran (Director), Pierre Caloz (COO), Ricardo Dolmetsch (Insider), Robert Gut (Director), Rachelle Jacques (Director), Matthew Kapusta (CEO), Jack Kaye (Director), Christian Klemt (CFO), Alexander Kuta, III (VP), David Meek (Director), Kylie O'Keefe (Chief Customer and Strategy Officer), Leonard Post (Director), Jeannette Potts (Insider), and Jeremy Springhorn (Director). Learn More on uniQure's active insiders.
Are insiders buying or selling shares of uniQure?
In the last twelve months, insiders at the biotechnology company sold shares 36 times. They sold a total of 829,188 shares worth more than $31,835,011.35. The most recent insider tranaction occured on July, 2nd when CEO Matthew C Kapusta sold 21,082 shares worth more than $952,063.12. Insiders at uniQure own 4.7% of the company.
Learn More about insider trades at uniQure. Information on this page was last updated on 7/2/2026.
